Harbour BioMed and BioMap Announce Joint Venture MegaStream TechBio to Advance AI-Driven Complex Biologics Pipeline

On June 15, Harbour BioMed announced the establishment of a multi-layered, long-term comprehensive strategic partnership with BioMap. The two companies will engage in all-around cooperation (“Strategic Cooperation”) centered on artificial intelligence (“AI”)-driven discovery and development of complex macromolecular drugs, aiming to systematically address key R&D bottlenecks in next-generation innovative therapies and jointly build an AI-driven R&D ecosystem with global leading competitiveness.

In accordance with the strategic cooperation framework,Harbour BioMedTogether with BioMap, we will jointly establish a next-generation AI-driven pipeline R&D company targeting the global market—MegaStream TechBio (“MegaStream”). MegaStream will integrate “exclusive big data × proprietary large models × extensive innovative pipeline portfolios” and build an AI R&D engine centered on an advanced, integrated intelligent dry-wet closed-loop experimental discovery platform, as well as personalized, multimodal, multi-attribute generative large models. MegaStream will focus on major unmet clinical needs in cardiovascular diseases, kidney diseases, oncology, and anti-aging, aiming to develop First-in-Class (“FIC”) and Best-in-Class (“BIC”) assets as its core R&D benchmarks.

As the lead initiator,Harbour BioMedIt will grant MegaStream access to its globally exclusive fully human antibody platform, extensive expertise in target biology, and global clinical development capabilities. BioMap will serve as a co-initiator, providing foundational AI technology empowerment, model engineering support, and intelligent R&D capabilities to help the company accelerate pipeline development. The initial pipeline of MegaStream is expected to comprise both AI-driven drug discovery projects from prior collaborations between the two parties and newly initiated AI-native pipeline projects. In accordance with industry standards, the initiating parties will be entitled to potential upfront payments, success-based milestone payments, and royalty sharing. Furthermore, MegaStream’s core management team is expected to consist of senior executives from multinational biopharmaceutical companies and leading experts in the field of artificial intelligence, with relevant personnel currently being onboarded.

Harbour BioMedThe Board of Directors believes that strategic cooperation representsHarbour BioMedThe further deepening of the existing cooperation with BioMap is expected to strengthenHarbour BioMedAI-powered discovery engine, expandingHarbour BioMedApplication Scenarios of the Technology Platform, and Strong SupportHarbour BioMedStrategy for Developing Differentiated Next-Generation Complex Macromolecular Drugs.

Follow the official account below to see the world!